Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, an AI biotech company, has secured $311 million in funding, valuing the company at $2 billion. This investment will be used to bring more nature-derived AI-discovered drugs into clinical trials. Currently, Enveda is testing two drugs in clinical trials: one for skin conditions and another for preserving weight loss after stopping GLP-1 therapies.